| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PIM3 |
| Uniprot No | Q86V86 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-326aa |
| 氨基酸序列 | MLLSKFGSLAHLCGPGGVDHLPVKILQPAKADKESFEKAYQVGAVLGSGG FGTVYAGSRIADGLPVAVKHVVKERVTEWGSLGGATVPLEVVLLRKVGAA GGARGVIRLLDWFERPDGFL LVLERPEPAQDLFDFITERGALDEPLAR RFFAQVLAAVRHCHSCGVVHRDIKDENLLVDLRSGELKLIDFGSGALLKD TVYTDFDGTRVYSPPEWIRYHRYHGRSATVWSLGVLLYDMVCGDIPFEQD EEILRGRLLFRRRVSPECQQLIRWCLSLRPSERPSLDQIAAHPWMLGADG GVPESCDLRLCTLDPDDVASTTSSSESL |
| 预测分子量 | 65 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于PIM3重组蛋白的参考文献摘要概括：
1. **文献名称**：*Expression and Purification of Recombinant PIM3 Kinase for Structural Studies*
**作者**：Chen et al.
**摘要**：该研究报道了通过大肠杆菌表达系统高效表达人源PIM3重组蛋白的优化方法，并利用镍柱亲和层析技术纯化获得高纯度蛋白，用于后续激酶活性测定及晶体结构解析。
2. **文献名称**：*Functional Characterization of PIM3 Recombinant Protein in Cancer Cell Survival*
**作者**：Rodríguez-López et al.
**摘要**：通过体外实验证明重组PIM3蛋白可磷酸化凋亡相关蛋白BAD，抑制肿瘤细胞凋亡，并验证其在肝癌细胞系中促进增殖的作用，为靶向PIM3的癌症治疗提供依据。
3. **文献名称**：*Development of a High-Throughput Screening Assay Using Recombinant PIM3 for Inhibitor Discovery*
**作者**：Wang & Thompson
**摘要**：研究团队建立了一种基于重组PIM3蛋白的体外激酶活性检测体系，用于高通量筛选小分子抑制剂，成功鉴定出多个具有纳摩尔级抑制活性的先导化合物。
(注：以上文献信息为示例性概括，具体研究需以实际发表的论文为准。)
**Background of PIM3 Recombinant Protein**
PIM3 (Proviral Integration site for Moloney murine leukemia virus 3) is a serine/threonine kinase belonging to the PIM kinase family, which includes PIM1. PIM2. and PIM3. These kinases are evolutionarily conserved and play critical roles in regulating cell survival, proliferation, and apoptosis. PIM3 shares structural and functional similarities with its family members, characterized by a conserved kinase domain and ATP-binding pocket. Unlike many kinases, PIM3 lacks regulatory domains, rendering it constitutively active upon translation. Its expression is primarily regulated at the transcriptional and translational levels, often induced by growth factors, cytokines, and oncogenic signals such as the JAK/STAT and PI3K/Akt pathways.
PIM3 is implicated in various cancers, including pancreatic, liver, and prostate cancers, where its overexpression correlates with tumor progression, metastasis, and drug resistance. It promotes oncogenesis by phosphorylating substrates involved in cell cycle regulation (e.g., CDC25A), apoptosis inhibition (e.g., BAD), and metabolic reprogramming. Additionally, PIM3 interacts with other signaling pathways, such as mTOR and c-MYC, to enhance cell survival under stress conditions.
Recombinant PIM3 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce functional kinase for *in vitro* studies. Purification typically involves affinity chromatography, yielding high-purity protein for structural analysis, enzymatic activity assays, and inhibitor screening. Its recombinant form is pivotal for deciphering PIM3's mechanistic roles in disease and developing targeted therapies. As PIM3 inhibitors gain traction in preclinical studies, recombinant PIM3 remains a vital tool for validating drug candidates and understanding resistance mechanisms in oncology research.
×
